Search results
Results from the WOW.Com Content Network
For Aetna, the company has seen higher utilization costs hamper Aetna's margins this year. Insurers typically prefer, and are required by the Affordable Care Act, to keep about 20% of healthcare ...
CVS CEO Larry Merlo had been named to run the combined company. [30] 2018: In November, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with ...
CVS Health has about 3.5 million people in that business through its Aetna arm. Health insurers started warning last year about higher-than-expected costs in their Medicare Advantage plans.
Aetna Inc. (/ ˈ ɛ t n ə / ET-nə) is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.
CVS’s acquisition of Aetna and ownership of PBM CVS Caremark have drawn significant criticism, with opponents arguing that this model monopolizes key aspects of the healthcare market. The three largest PBMs in the United States are UnitedHealth Group 's Optum , CVS Health’s CVS Caremark, and Cigna 's Express Scripts .
CVS Health is in talks to purchase Aetna, one of the five large publicly traded health-insurance companies, according to a new report. CVS is reportedly considering buying health-insurance giant ...
CVS Health Corp. still runs one of the nation’s largest drugstore chains and a huge pharmacy benefit management business that operates prescription drug coverage. It also covers nearly 27 million people through its Aetna insurance arm. Overall, the company's profit dropped more than 7% to $1.77 billion in the quarter.
In 2017, CVS Health announced a merger with Aetna, completing in November 2018. [38] The takeover of PBMs have drawn regulator resistance because of fears they foster an anti-competitive environment. Insurance companies have charged that the PBM model has contributed to high drug prices because PBMs take a commission on each transaction. [39] [40]